Impact of the Adipokine Adiponectin and the Hepatokine Fetuin-A on the Development of Type 2 Diabetes: Prospective Cohort- and Cross-Sectional Phenotyping Studies

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Stefan, N., Q. Sun, A. Fritsche, J. Machann, F. Schick, F. Gerst, C. Jeppesen, et al. 2014. “Impact of the Adipokine Adiponectin and the Hepatokine Fetuin-A on the Development of Type 2 Diabetes: Prospective Cohort- and Cross-Sectional Phenotyping Studies.” PLoS ONE 9 (3): e92238. doi:10.1371/journal.pone.0092238. http://dx.doi.org/10.1371/journal.pone.0092238.

Published Version
doi:10.1371/journal.pone.0092238

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12064378

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Impact of the Adipokine Adiponectin and the Hepatokine Fetuin-A on the Development of Type 2 Diabetes: Prospective Cohort- and Cross-Sectional Phenotyping Studies

Norbert Stefan1,2,3*, Qi Sun4,5, Andreas Fritsche1,2,3, Jürgen Machann1,6, Fritz Schick6, Felicia Gerst1,2,3, Charlotte Jeppesen7,3, Hans-Georg Joost8,3, Frank B. Hu4,5,9, Heiner Boeing10, Susanne Ullrich1,2,3, Hans-Ulrich Häring1,2,3, Matthias B. Schulze7,3

1 Department of Internal Medicine IV, University Hospital Tübingen, Tübingen, Germany, 2 Institute of Diabetes Research and Metabolic Diseases, Member of the German Center for Diabetes Research (DZD), Tübingen, Germany, 3 Deutsches Zentrum für Diabetesforschung (DZD), Neuherberg, München, Germany, 4 Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, United States of America, 5 Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 6 Section on Experimental Radiology, University Hospital Tübingen, Tübingen, Germany, 7 Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany, 8 Department of Pharmacology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany, 9 Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America, 10 Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany

Abstract

Background: Among adipokines and hepatokines, adiponectin and fetuin-A were consistently found to predict the incidence of type 2 diabetes, both by regulating insulin sensitivity.

Objective: To determine to what extent circulating adiponectin and fetuin-A are independently associated with incident type 2 diabetes in humans, and the major mechanisms involved.

Methods: Relationships with incident diabetes were tested in two cohort studies: within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study (628 cases) and the Nurses’ Health Study (NHS; 470 cases). Relationships with body fat compartments, insulin sensitivity and insulin secretion were studied in the Tübingen Lifestyle Intervention Program (TULIP; N = 358).

Results: Circulating adiponectin and fetuin-A, independently of several confounders and of each other, associated with risk of diabetes in EPIC-Potsdam (RR for 1 SD: adiponectin: 0.45 [95% CI 0.37–0.54], fetuin-A: 1.18 [1.05–1.32]) and the NHS (0.51 [0.42–0.62], 1.35 [1.16–1.58]). Obesity measures considerably attenuated the association of adiponectin, but not of fetuin-A. Subjects with low adiponectin and concomitantly high fetuin-A had the highest risk. Whereas both proteins were independently (both p < 1.8 × 10^-7) associated with insulin sensitivity, circulating fetuin-A (r = –0.37, p = 0.0004), but not adiponectin, associated with insulin secretion in subjects with impaired glucose tolerance.

Conclusions: We provide novel information that adiponectin and fetuin-A independently of each other associate with the diabetes risk. Furthermore, we suggest that they are involved in the development of type 2 diabetes via different mechanisms, possibly by mediating effects of their source tissues, expanded adipose tissue and nonalcoholic fatty liver.

Citation: Stefan N, Sun Q, Fritsche A, Machann J, Schick F, et al. (2014) Impact of the Adipokine Adiponectin and the Hepatokine Fetuin-A on the Development of Type 2 Diabetes: Prospective Cohort- and Cross-Sectional Phenotyping Studies. PLoS ONE 9(3): e92238. doi:10.1371/journal.pone.0092238

Editor: Marta Letizia Hribal, University of Catanzaro Magna Graecia, Italy

Received October 28, 2013; Accepted February 20, 2014; Published March 18, 2014

Copyright: © 2014 Stefan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The recruitment phase of the EPIC-Potsdam Study was supported by the Federal Ministry of Science, Germany (01 EA 9401) and the European Union (SOC 95201408 05F02). The follow-up of the EPIC-Potsdam Study was supported by the German Cancer Aid (70-2488-Ha I) and the European Community (SOC 98200769 05F02). The NHS was supported by research grants (CA87969, CA44449, DK58845, DK58785, and P30 DK46200) from the National Institutes of Health. Q.S. was supported by a career development award K99HL098459 from the National Heart, Lung, and Blood Institute and a Pilot and Feasibility program sponsored by the Boston Obesity Nutrition Research Center (DK46200). The TULIP was supported by grants from the German Research Foundation (DFG; KFO 114, and a Heisenberg-Professorship to NS: STE 1096/3-1). The study was also supported by the German Federal Ministry of Education and Research to the German Center for Diabetes Research (DZD eV) and a grant from the Diabetes Stiftung (270-07-10). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: norbert.stefan@med.uni-tuebingen.de
Introduction

Among several pathways involved in the pathogenesis of the epidemiically spreading disease type 2 diabetes, an altered secretory pattern of the expanded and inflamed adipose tissue is thought to be important for the regulation of insulin sensitivity and subclinical inflammation in various tissues [1]. In this respect adiponectin has gained much attention in the past years because the circulating levels of this adipokine are not only markers of type 2 diabetes risk, but because adiponectin is strongly involved in its progression [2]. In analogy to dysregulated adipose tissue [2–4], there is increasing evidence that nonalcoholic fatty liver disease (NAFLD), which predictive of metabolic diseases [5–10], is also associated with an altered secretory pattern of proteins, which can be referred to as hepatokines, and which are both markers of the disease, and are involved in its pathophysiology [11]. Among them fetuin-A gained much attention during the recent years because of its association with type 2 diabetes and cardiovascular disease risk [12–17], and its important role in the pathogenesis of insulin resistance and subclinical inflammation [18–23].

In the present study we now asked two questions: first, to what extent are circulating levels of these proteins related to incident type 2 diabetes independently of each other? Second, because the circulating levels of these two proteins strongly reflect the dysregulation of their source tissues, adipose tissue and liver, can they be used to estimate the contribution of expanded and inflamed adipose tissue and NAFLD to the pathogenesis of insulin resistance and impaired beta cell function?

For this we investigated associations of circulating adiponectin and fetuin-A with incident type 2 diabetes by applying a head to head comparison of these proteins in two large cohort studies, the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study and the Nurses’ Health Study (NHS). In addition, we studied the independent relationships of the circulating levels of these proteins with precisely measured body fat mass and distribution, liver fat content, insulin sensitivity and insulin secretion in subjects of the Tübingen Lifestyle Intervention Program (TULIP).

Subjects and Methods

EPIC-Potsdam study

The EPIC-Potsdam Study is part of the multi-centre prospective cohort study EPIC [24]. In Potsdam, Germany, 27,548 subjects (16,644 women and 10,904 men) were recruited from the general population between 1994 and 1998. The age range was 35–65 years in women and 40–65 years in men. The baseline examination included anthropometric measurements, a personal interview including questions about prevalent diseases, and a questionnaire about socio-demographic and lifestyle characteristics [13]. Follow-up questionnaires were sent out every 2 to 3 years to identify incident cases of type 2 diabetes. All incident cases of type 2 diabetes identified were verified by treating physicians. Biochemical measurements were carried out in a case-cohort design nested within the cohort, details of which have been published previously [13]. Briefly, we randomly selected a subcohort of 2,500 individuals of whom 2,095 were non-diabetic at baseline (based on self-report and blood glucose determinations) and had anamnestic, anthropometrical and metabolic data for analysis. Of the 494 incident diabetes cases identified in the full cohort during an average follow-up of 7 years 628 remained for analyses after similar exclusions. Informed consent was obtained from all participants, and approval was given by the Ethical Committee of the State of Brandenburg, Germany.

NHS

A total of 121,700 registered nurses living in one of 11 populous U.S. states composed the NHS when they responded to a questionnaire inquiring about their medical history and lifestyle characteristics in 1976 [15]. In 2000–2001, 18,717 NHS participants aged 53–79 years provided blood samples. Among these participants, a prospective, nested, case-control study was conducted to examine plasma biomarkers in relation to type 2 diabetes risk. After excluding women with self-reported prevalent diabetes, cardiovascular disease, or cancer at baseline, 470 cases of type 2 diabetes cases from the date of blood draw through June 2006 were prospectively identified and confirmed. Risk-set sampling was used to randomly select one control for each case from the rest of population who remained free of diabetes when the case was diagnosed; the probability of being selected as a control is proportional to the length of follow-up. Cases and controls were further matched for age at blood draw (61 year), date of blood draw (63 months), fasting status (fast for 8 h or not), and race (white or other races) [15]. The study protocol was approved by the institutional review board of the Brigham and Women’s Hospital and the Human Subjects Committee Review Board of Harvard School of Public Health.

TULIP

A total of 358 Caucasians, who participated in the Tübingen Lifestyle Intervention Program (TULIP) [24], were included in the present analyses because they fulfilled at least one of the following criteria: a family history of type 2 diabetes, a BMI>27 kg/m², previous diagnosis of impaired glucose tolerance or gestational diabetes. Informed written consent from subjects participating in the Tübingen studies was obtained and the Ethical Committee of the University of Tübingen, Germany had approved the protocols.

Anthropometrics and metabolic parameters were measured as previously described [13,25,26]. Glucose tolerance was determined according to the 1997 World Health Organization diagnostic criteria [27]. Insulin sensitivity from the OGTT was estimated as proposed by Matsuda and DeFronzo [28]. In a subgroup (N = 244) insulin sensitivity was also measured during a euglycemic, hyperinsulinemic clamp [26]. The insulinogenic index, a precise estimate of glucose-induced insulin secretion, was assessed from the OGTT as follows: (insulin at 30 min-insulin at 0 min)/glucose at 30 min-glucose at 0 min).

Measurement of adiponectin and fetuin-A

In the EPIC-Potsdam study and in the TULIP study adiponectin levels were determined with enzyme-linked immunosorbent assays (ELISA, Linco Research, Inc., St Charles, MO). Fetuin-A levels were measured using an immunoturbidimetric method (BioVendor Laboratory Medicine, Modrlic, Czech Republic). In the NHS, both, adiponectin and fetuin-A levels were measured by enzyme immunoassays from R&D Systems (Minneapolis, MN).

Statistical analyses

In the EPIC Study and the NHS adiponectin and fetuin-A levels were categorized into quintiles based on subcohort or control participants. Hazard ratios as a measure of relative risk (RR) were computed using a weighted Cox proportional hazards model in EPIC-Potsdam, modified for the case-cohort design according to the Prentice method. Age was the underlying time variable in the counting processes, with entry defined as the subjects’ age at the time of recruitment and exit defined as age at the diagnosis of diabetes, or censoring. In NHS, odds ratios were calculated using
We computed RRs/ORs for each quintile of adiponectin and fetuin-A compared with the lowest quintile. The significance of linear trends across quintiles of adiponectin and fetuin-A was tested by assigning each participant the median value for the quintile and modeling this value as a continuous variable. Because this analysis indicated no departure from linearity, we also considered adiponectin and fetuin-A as continuous variables estimating the RR/OR associated with an increment of 1 SD. We used information on covariates obtained from the baseline examination in multivariate analyses, namely sex, education, physical activity, smoking, and alcohol intake. Analyses in NHS were further adjusted for other matching factors beyond age (race, fasting status, time of blood drawing), as well as body mass index (BMI), waist circumference (cm), smoking status (current smoker, past smoker, non-smoker), physical activity (in tertiles), alcohol use (abstainer, <5.0 g/day, 5.0–14.9 g/day, ≥15.0 g/day), and education (registered nurse, bachelor, master and higher).

do[10.1371/journal.pone.0092238.t001

### Results

Association of circulating adiponectin and fetuin-A with diabetes incidence in the EPIC-Potsdam Study and the NHS

The adjusted RRs/ORs of type 2 diabetes for quintiles of fetuin-A and adiponectin in the EPIC-Potsdam study and the NHS are shown in table 1. Higher levels of fetuin-A were associated with an increased risk of diabetes, independent of adiponectin [RR/OR comparing extreme quintiles: EPIC-Potsdam: 1.23 [95% CI: 0.88–1.72], p for trend <0.01; NHS: 2.05 [1.24–3.37]]. Contrary, higher adiponectin levels were associated with lower risk of diabetes in both cohorts [RR/OR comparing extreme quintiles: EPIC-Potsdam: 0.20 [0.13–0.30]; NHS: 0.18 [0.10–0.32]]. Considering fetuin-A and adiponectin as continuous variables (per 1 SD increment), revealed a similar picture with consistent inverse associations for adiponectin and positive
associations for fetuin-A (Table 2). Adjustment for BMI and waist circumference attenuated the associations of adiponectin (by 29% in EPIC-Potsdam and 28% in NHS). However, the association of fetuin-A with diabetes risk was largely unaffected by adjustment for BMI and waist circumference (Table 2).

We then examined the joint effect of circulating adiponectin and fetuin-A by cross-classifying participants by both variables using sex-specific medians as cut-offs. The RR/OR for the combination of a high fetuin-A- and a low adiponectin level compared with the opposite extreme was 3.54 (95% CI: 2.54–4.95) in EPIC-Potsdam and 4.61 (2.97–7.30) in NHS (Figure 1, A/B). Tests for interaction were non-significant in both cohorts.

Cross-sectional relationships in the TULIP

The 358 TULIP subjects had a mean age of 46 years and a mean BMI of 30 kg m⁻². To investigate relationships of circulating adiponectin and fetuin-A levels with metabolic traits we performed analyses in the total population and in subjects with normal glucose tolerance (NGT) and impaired glucose tolerance (IGT) separately (Table 1 in File S1). The RR/OR for the combination of a high fetuin-A- and a low adiponectin level compared with the opposite extreme was 3.54 (95% CI: 2.54–4.95) in EPIC-Potsdam and 4.61 (2.97–7.30) in NHS (Figure 1, A/B). Tests for interaction were non-significant in both cohorts.

Table 2. Relative Risk of type 2 diabetes for plasma adiponectin and fetuin-A and attenuation of the risk by BMI and waist circumference.

|                      | Adiponectin | Fetuin-A |
|----------------------|-------------|----------|
|                      | RR/OR 1 SD  | % change |
|                      |             |          |
| **EPIC-Potsdam**     |             |          |
| Model 1 *            | 0.35        | Ref      |
| Model 1 + BMI        | 0.43        | +22.9    |
|                      | (0.29, 0.41)| (1.09, 1.34)|
| Model 1 + BMI + waist circumference | 0.45 | +28.6 | (0.37, 0.54) | (1.05, 1.32) |
| **Nurses’ Health Study** |             |          |
| Model 1             | 0.40        | Ref      |
| Model 1 + BMI       | 0.47        | +17.5    |
|                      | (0.39–0.57) | (1.18–1.61)|
| Model 1 + BMI + waist circumference | 0.51 | +27.5 | (0.42–0.62) | (1.16–1.58) |

*Relative Risk adjusted for age, sex, education (in or no training, vocational training, technical school, or technical college or university degree), occupational activity (light, moderate, heavy), sport activity (0, 0.1–4.0, >4.0 h/week), cycling (0, 0.1–2.4, 2.5–4.9, ≥5.0 h/week), smoking (never, past, current <20 cigarettes/d, current ≥20 cigarettes/d), and alcohol intake (0, 0–5.0, 5.1–10.0, 10.1–20.0, 20.1–40.0, >40.0 g/d).

Odds Ratio adjusted for matching factors, including age at blood draw (yrs), race (white or not), fasting status (yes, no), and time of blood drawing, as well as smoking status (current smoker, past smoker, non-smoker), physical activity (in tertiles), alcohol use (abstainer, <5.0 g/day, 5.0–14.9 g/day, ≥15.0 g/day), and education (registered nurse, bachelor, master and higher).

doi:10.1371/journal.pone.0092238.t002

Adiponectin, Fetuin-A and Risk of Type 2 Diabetes

Inclusion of BMI and waist circumference in the models attenuated the associations of circulating adiponectin (change of the β; OGTT: −37%, clamp: −31%) on insulin sensitivity, but less so of circulating fetuin-A (OGTT: −17%, clamp: −18%) (Table 3, models 2). Similar relationships were found when these analyses were performed in subjects with and without NAFLD (OGTT: total N = 291, NAFLD = 93; clamp: total N = 203, NAFLD = 63). Here inclusion of BMI and waist circumference in the models attenuated the associations of circulating adiponectin with insulin sensitivity, particularly in subjects without NAFLD (change of the β; OGTT: −52%, clamp: −34%), while this association was only slightly attenuated or even became stronger in the smaller group of subjects with NAFLD. Adiponectin and fetuin-A correlated only very weakly with waist circumference (r = 0.10, p = 0.06), total body fat mass (r = 0.07, p = 0.25), and visceral fat (r = 0.07, p = 0.20) mass. However, a positive correlation with liver fat content was found (r = 0.12, p = 0.04). In multivariate models including age and sex, both circulating adiponectin and fetuin-A were strongly and independently associated with insulin sensitivity estimated from the OGTT and measured during the clamp (Table 3, models 1).
1.42 [95% CI 1.09–1.85]) but not circulating adiponectin (0.88 [0.77–1.01]) or hs-CRP levels (1.04 [0.98–1.11]) to predict the insulin resistant state, independently of age, sex, BMI and waist circumference. Similar relationships were found when NGT and IGT were analyzed separately (data not shown).

When we divided participants by the medians of circulating adiponectin and fetuin-A levels, individuals with low adiponectin and high fetuin-A levels had the lowest insulin sensitivity compared to the other groups (Figure 1, C/D).

Relationships of circulating adiponectin and fetuin-A with insulin secretion. We next investigated whether circulating fetuin-A may be associated with glucose-induced insulin secretion in humans. In the total population circulating fetuin-A did not correlate with the insulinogetic index ($r$=0.01, $p=0.99$) when adjusted for age, gender and insulin sensitivity measured during the OGTT. However, this association depended on glucose tolerance status: while fetuin-A did not correlate with the insulinogetic index in subjects with NGT, a strong negative correlation between fetuin-A levels and the insulinogetic index was found in subjects with IGT ($r=-0.37$, $p=0.0004$) ($p$ for interaction $=0.024$) (Figure 2, A/B). No significant relationships were found for circulating adiponectin with the adjusted insulinogetic index (all $p>0.055$).

Discussion

During the last decade much effort has been made to identify important pathways involved in the natural history of type 2 diabetes. Thereby, several candidates were described, predominantly based on animal and on in-vitro studies [29–31]. However, often it was not possible to prove these pathways to be of high relevance for human metabolism. In human studies, on the other hand, several blood, genetic or phenotypic markers were found to predict incident type 2 diabetes [1–4]. Nevertheless, no precise mechanisms of action for several of these parameters are known and/or their predictive effect on the development of type 2 diabetes was either small or absent, which so far limits their potential in the prevention and the treatment of the disease.

Because these limitations largely do not apply to the adipokine adiponectin and the hepatokine fetuin-A, we here investigated to what extent circulating adiponectin and fetuin-A determine incident type 2 diabetes, independently of each other. Towards
sensitivity may be a result of inflamed NAFLD [11,32–35].

information from our and other studies suggest that the increase considerably depend on body fatness. Rather the available

the association of fetuin-A with diabetes risk does not appear to

in part the effect of obesity on the type 2 diabetes risk. In contrast,

obesity, our data support that the adiponectin levels confer at least

attenuated after accounting for estimates of overall and visceral

adiponectinemia, but not of circulating fetuin-A, was considerably

with Caucasian origin. Because the strength of association of

fetuin-A to regulate insulin sensitivity, we confirmed that the

levels. Based on the known properties of adiponectin and

fetuin-A to regulate insulin sensitivity, we confirmed that the

circulating levels of these proteins were independently of each

other associated with insulin sensitivity, estimated from the OGGT

or measured by a euglycemic, hyperinsulinemic clamp. In

agreement with the findings from the EPIC-Potsdam study and

the NHS, the relationship of circulating adiponectin, but not of

fetuin-A, was considerably attenuated after accounting for

measurements of body fat content and distribution. Consequently

we asked the question whether circulating fetuin-A may be a better

predictor of insulin sensitivity than circulating adiponectin in

subjects who are non-obese and could confirm this hypothesis in

our study.

Having found strong independent associations of circulating

adiponectin and fetuin-A, the two proteins that regulate insulin

secretion in our subjects. Based on the knowledge that subjects

with IGT have an impaired beta cell function [37,38], we then
tested the hypothesis that fetuin-A is particularly relevant

with IGT have an impaired beta cell function [37,38], we then
tested the hypothesis that fetuin-A is particularly relevant

specifically in this population that is at very high risk for the
disease. Indeed, when we separated the individuals in those with

NGT and IGT, a strong negative relationship of fetuin-A with

disease. Indeed, when we separated the individuals in those with

NGT and IGT, a strong negative relationship of fetuin-A with

insulin secretion was found in subjects with IGT.

NGT and IGT, a strong negative relationship of fetuin-A with

insulin secretion was found in subjects with IGT.

What is the relevance of our data for clinicians and researchers?
Because the relative risk of incident diabetes was much higher for
the combination of a high fetuin-A and a low adiponectin level,
than for the single circulating level of each protein, it may be

important for clinicians to measure both proteins when it comes to the prediction of the risk of future type 2 diabetes. Whether fetuin-A and adiponectin improve prediction of diabetes risk beyond waist circumference and other classical risk factors remains, however, uncertain. Furthermore, fetuin-A may become an important determinant of insulin resistant states, particularly in non-obese subjects where adiponectin and hs-CRP levels lost their strong predictive power in our study.

For researchers we provide novel information that adiponectin and fetuin-A are independently involved in the pathogenesis of type 2 diabetes. Both proteins impact on the development of the disease predominantly be the regulation of subclinical inflammation. Furthermore, we have support for the hypothesis that they mediate the effects of their source tissues, expanded adipose tissue and inflamed nonalcoholic fatty liver on glucose metabolism and cardiovascular disease. In addition, we provide explorative information about a putatively newly identified cross-talk of the liver with the endocrine function of the pancreas. Whether there are direct effects of fetuin-A on signalling cascades in beta cells or whether fetuin-A induces a chronic pro-inflammatory process in the human islets needs to be investigated in future studies.

Some possible limitations of our findings have to be considered. The potential of residual confounding applies to our study as it does to observational studies in general. We adjusted for a large variety of known risk factors. Although fetuin-A and adiponectin remained significantly associated with diabetes risk, we cannot rule out that other unmeasured factors or that imprecision in the measurement of covariates explain this observation. Also, we only had a single blood drawing which might have introduced random measurement errors in determining fetuin-A and adiponectin. The lack of repeated measurements may have led to an underestimation of the observed associations. In conclusion, our findings support that the adipokine adiponectin and the hepatokine fetuin-A are reliable predictors of incident type 2 diabetes and insulin resistance, and that they are strongly and independently of each other involved in their pathogenesis. Moreover, we could provide indirect support that adiponectin mediates, at least in part, the impact of dysregulated and expanded visceral fat on metabolism, whereas increased fetuin-A levels are largely a result of NAFLD. Finally, we provided novel exploratory information that fetuin-A may play a role in the pathogenesis of type 2 diabetes by affecting insulin secretion.

Supporting Information

Table S1 Characteristics of the TULIP study participants.

Author Contributions

Conceived and designed the experiments: NS QS AF MBS FS FBH HB HGJ HUH. Performed the experiments: NS QS AF JM CJ FG SU MBS. Analyzed the data: NS QS MJ MBS. Wrote the paper: NS QS MBS.

References

1. Nolan CJ, Damm P, Prentki M (2011) Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 378: 169–181.
2. Turer AT, Scherer PE (2012) Adiponectin: mechanistic insights and clinical implications. Diabetologia 55: 319–326.
3. Kadwaki T, Yamauchi T, Kubota N, Hara K, Ueki K, et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 116: 1784–1792.
4. Ouchi N, Parker JL, Lagus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 11: 85–97.
5. Roden M (2006) Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2: 335–340.
6. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, et al. (2007) Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133: 496–506.
7. Kotronen A, Yki-Jarvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 28: 27–38.
8. Perseghin G (2011) Lipids in the wrong place: visceral fat and nonalcoholic steatohepatitis. Diabetes Care 34 Suppl 2: S367–370.
9. Stefan N, Haring HU (2011) The metabolically benign and malignant fatty liver. Diabetes 60: 2011–2017.
10. Cusi K (2012) Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142: 711–725.e6.
11. Stefan N, Ha¨ring HU (2013) The role of hepatokines in metabolism. Nat Rev Endocrinol. 9: 144–152.
12. Ix JH, Wasel CL, Kanaya AM, Vittinghoff E, Johnson KC, et al. (2008) Fetuin-A and incident diabetes mellitus in older persons. JAMA300: 182–180.
13. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, et al. (2008) Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57: 2762–2767.
14. Ix JH, Biggs ML, Murali KJ, Kizer JR, Zieman SJ, et al. (2012) Association of fetuin-a with incident diabetes mellitus in community-living older adults: the cardiovascular health study. Circulation 125: 2316–2322.
15. Sun Q, Cornelis MC, Manson JE, Hu FB (2913) Plasma Levels of Fetuin-A and Hepatic Enzymes and Risk of Type 2 Diabetes in Women in the U.S. Diabetes 62: 49–53.
16. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, et al. (2008) Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 118: 2355–2362.
17. Fisher E, Stefan N, Saar K, Drogan D, Schulze MB, et al. (2009) Association of AHS1 gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study. Circ Cardiovasc Genet. 2: 607–613.
18. Aubeger P, Falquerho L, Contreres JO, Pages G, Le Cam G, et al. (1989) Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 58: 631–640.
19. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, et al. (2008) Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One 3: e1765.
20. Dasgupta S, Bhattacharya S, Biswas A, Majumdar SS, Mokhopedhay S, et al. (2010) NF-kappaB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochern J. 429: 451–462.
21. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, et al. (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 18:1279–1283.
22. Stefan N, Ha¨ring HU (2013) Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med. 19: 394–395.
23. Heinrichsdorff J, Olefsky JM (2008) The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev. 29: 42–61.
24. Rees DA, Alcolado JC (2012) Animal models of diabetes mellitus. Diabet Med. 29: 359–370.
25. Islam MS, Wilson RD (2012) Experimentally induced rodent models of type 2 diabetes. Methods Mol Biol. 933: 161–174.
26. Reinehr T, Roth CL (2008) Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab. 93: 507–510.
27. Staiger K, Stefan N, Henninge AM, Staiger H, Machann J, Schick F, et al. (2006) Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance. Endocrinology 153: 2974–2984.
28. Staiger K, Stefan N, Henninge AM, Staiger H, Machann J, Schick F, et al. (2006) Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29: 653–657.
29. Samuel VT, Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148: 852–871.
30. Ou HY, Wu HT, Hung HC, Yang YC, Wu JS, et al. (2012) Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance. J Clin Endocrinol Metab. 90: 6707–6713.
31. Eizirik DL, Cardozo AK, Coop M (2008) The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev. 29: 42–61.
32. Talaks Ag, Herder C, Rathmann W, Brunner EJ, Kivimaki M (2012) Prediabetes: a high-risk state for diabetes development. Lancet 379: 2279–2290.